SCHEMBL5223810

SCHEMBL5223810

O=C1CCN(C(=O)O)[C@H](C(=O)O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15542290 1.00
SCHEMBL5224593 1.00
SCHEMBL20723785 0.82 ALDH1A1 (0.35)
SCHEMBL20723786 0.82 ALDH1A1 (0.35)
SCHEMBL4418517 0.80 MMP2 (0.46)
SCHEMBL30346218 0.80 TSHR (0.39)
SCHEMBL22518861 0.80
SCHEMBL22518860 0.80
SCHEMBL1250785 0.79 MMP2 (0.36)
SCHEMBL6921106 0.79 MMP2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117897388-A BTK protein degradation agent 广州麓鹏制药有限公司 2024-04-16 CN disclosed
US-20240058457-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2024-02-22 US disclosed
US-20230357271-A1 MACROCYCLIC COMPOUND ASAHI KASEI PHARMA CORPORATION (JP) 2023-11-09 US disclosed
EP-4263552-A1 BTK DEGRADER Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) 2023-10-25 EP disclosed
EP-4223368-A1 MACROCYCLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2023-08-09 EP disclosed
WO-2023137225-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2023-07-20 WO disclosed
WO-2022133184-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2022-06-23 WO disclosed
EP-3558980-B1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2021-01-27 EP disclosed
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-10-27 US disclosed
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-03-26 US disclosed
US-20180162855-A1 PDD AND BPD COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2018-06-14 US disclosed
EP-2864318-B1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS MACROPHAGE PHARMA LTD (GB) 2017-08-09 EP disclosed
US-20170157118-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS MACROPHAGE PHARMA LIMITED (GB) 2017-06-08 US disclosed
CN-104583199-B 2-aminopyrazine derivatives as CSF-1R kinase inhibitors 色品疗法有限公司 2017-05-10 CN disclosed
US-9604940-B2 2-aminopyrazine derivatives as CSF-1R kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2017-03-28 US disclosed
US-20150368210-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2015-12-24 US disclosed
EP-2864318-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS Chroma Therapeutics Ltd. (GB) 2015-04-29 EP disclosed
WO-2014001802-A1 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2014-01-03 WO disclosed
EP-1814893-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2007-08-08 EP disclosed
WO-2006055070-A2 NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2006-05-26 WO disclosed